Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > I am a bit bipolar

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Jun 24, 2021 7:38am

150 Views

Post# 33440197

RE:RE:RE:RE:RE:RE:RE:RE:I am a bit bipolar

Agreed, that is a poweful and acurate statement that any retail investor like myself would get pretty excited about.

realitycheck4u wrote: "Once SORT is proven to be the "key" to enter cancer cells, mix and match other molecules against other types of cancer would become a new paradigm for cancer treatment."

That should be in their presentations

JayjayUSA12007 wrote:
"...If 1902 succeeeds then the whole platform increases in value. You don't need to double or triple your clinical costs by adding a 2nd or 3rd molecule in order to see massive gains...."

Excellent point, Qwerty22 ! Once SORT is proven to be the "key" to enter cancer cells, mix and match other molecules against other types of cancer would become a new paradigm for cancer treatment.